上海医药
(601607)
| 流通市值：366.79亿 | | | 总市值：702.36亿 |
| 流通股本：19.37亿 | | | 总股本：37.08亿 |
| 报告期 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 35,744,328,038.57 | 33,822,817,448.38 | 36,676,143,387.18 | 30,040,144,079.63 |
| 衍生金融资产 | 16,224,786.35 | 771,972.13 | 385,057.56 | 1,596,097.37 |
| 应收票据及应收账款 | 80,251,310,784.39 | 84,491,008,709.25 | 82,655,633,117.01 | 82,940,797,362.36 |
| 其中：应收票据 | 1,122,105,045.23 | 1,417,341,608.92 | 1,708,323,018.07 | 1,694,769,858.77 |
| 应收账款 | 79,129,205,739.16 | 83,073,667,100.33 | 80,947,310,098.94 | 81,246,027,503.59 |
| 应收款项融资 | 1,965,669,770.02 | 1,562,696,371.46 | 1,571,195,939.75 | 2,314,411,123.29 |
| 预付款项 | 1,947,402,427.71 | 3,119,660,448.14 | 3,630,194,424.76 | 7,201,196,074.37 |
| 其他应收款合计 | 3,106,695,609.03 | 3,189,477,884.12 | 3,433,826,774.03 | 2,958,949,690.25 |
| 应收股利 | 94,189,935.96 | 195,966,901.16 | 302,781,923.43 | 239,151,615.4 |
| 存货 | 38,943,669,737.08 | 37,576,064,093.47 | 35,255,345,466.35 | 33,838,090,831.88 |
| 一年内到期的非流动资产 | 83,611,615.14 | 50,884,816.23 | 53,897,478.95 | 53,719,083.58 |
| 其他流动资产 | 1,131,264,653.68 | 1,411,698,621.81 | 1,151,265,475.81 | 921,439,376.62 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 171,823,107,421.97 | 173,787,729,817.04 | 171,602,970,409.07 | 167,405,500,979.62 |
| 非流动资产: | | | | |
| 长期应收款 | 386,244,506.89 | 574,404,856.79 | 596,539,887.44 | 225,742,256.59 |
| 长期股权投资 | 8,066,844,872.89 | 8,134,057,845.44 | 8,153,381,607.96 | 8,554,441,849.79 |
| 其他权益工具投资 | 43,899,340.7 | 55,531,056.23 | 66,567,416.94 | 66,122,515.83 |
| 其他非流动金融资产 | 1,724,668,131.23 | 2,191,288,189.48 | 2,218,578,729.4 | 2,193,496,868.53 |
| 投资性房地产 | 366,010,300.23 | 340,382,391.1 | 332,447,976.21 | 336,475,559.79 |
| 固定资产 | 14,911,045,205.84 | 12,573,843,576.59 | 11,810,316,923.72 | 11,932,590,285.81 |
| 在建工程 | 2,148,651,608.6 | 3,916,553,388 | 4,365,869,886.92 | 4,203,714,978.23 |
| 生产性生物资产 | 133,381,840.87 | 133,897,582.49 | 134,881,369.15 | 135,967,282.47 |
| 使用权资产 | 1,981,731,618.35 | 2,101,631,832.18 | 2,025,716,000.15 | 2,072,619,147.12 |
| 无形资产 | 5,617,462,430.33 | 5,754,056,580.77 | 5,814,631,801.17 | 5,882,602,167.64 |
| 开发支出 | 215,324,899.96 | 220,204,537.8 | 222,054,998.18 | 306,865,862.17 |
| 商誉 | 11,145,586,135.68 | 11,407,687,171.91 | 11,391,892,507.67 | 11,389,451,260.29 |
| 长期待摊费用 | 534,566,477.24 | 437,411,781.27 | 435,840,466.68 | 460,967,672.21 |
| 递延所得税资产 | 1,627,529,013.21 | 1,805,242,413.09 | 1,763,669,723.7 | 1,865,602,007.62 |
| 其他非流动资产 | 483,376,344.18 | 307,422,771.52 | 400,512,124.7 | 384,796,050.71 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 49,386,322,726.2 | 49,953,615,974.66 | 49,732,901,419.99 | 50,011,455,764.8 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 221,209,430,148.17 | 223,741,345,791.7 | 221,335,871,829.06 | 217,416,956,744.42 |
| 流动负债: | | | | |
| 短期借款 | 38,064,098,967.71 | 38,807,536,293.8 | 40,511,004,682.9 | 37,410,464,967.73 |
| 衍生金融负债 | 1,598,178.46 | 11,984,504.4 | 5,353,697.43 | 1,325,977.1 |
| 应付票据及应付账款 | 59,482,920,479.29 | 61,687,654,031.72 | 58,455,897,486.79 | 57,352,454,485.76 |
| 其中：应付票据 | 9,241,133,347.89 | 6,758,318,639.99 | 6,177,036,647.58 | 6,285,050,477.84 |
| 应付账款 | 50,241,787,131.4 | 54,929,335,391.73 | 52,278,860,839.21 | 51,067,404,007.92 |
| 合同负债 | 1,562,036,773.57 | 1,441,898,922.84 | 1,261,569,500.59 | 1,600,676,575.84 |
| 应付职工薪酬 | 1,796,347,060.73 | 1,590,633,832.38 | 1,425,611,221.07 | 1,304,345,917.97 |
| 应交税费 | 1,264,015,312.92 | 952,109,160.15 | 880,421,328.72 | 1,234,684,244.17 |
| 其他应付款合计 | 16,797,359,516.09 | 16,903,793,399.87 | 18,156,000,542.69 | 16,618,535,528.09 |
| 应付股利 | 381,062,451.26 | 319,621,352.73 | 1,752,675,812.65 | 245,171,287.95 |
| 一年内到期的非流动负债 | 842,162,528.36 | 1,927,352,821.03 | 2,248,482,785.62 | 3,571,794,964.57 |
| 其他流动负债 | 6,227,847,461.97 | 6,209,160,029.63 | 6,159,773,978.4 | 6,179,146,404.34 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 126,038,386,279.1 | 129,532,122,995.82 | 129,104,115,224.21 | 125,273,429,065.57 |
| 非流动负债: | | | | |
| 长期借款 | 8,331,334,115.57 | 7,689,775,408.79 | 6,599,380,587.16 | 6,620,983,465.48 |
| 租赁负债 | 1,396,299,515.58 | 1,619,054,561.52 | 1,497,291,463.6 | 1,514,473,037.53 |
| 长期应付款 | 9,153,417.88 | 9,082,039.42 | 8,782,360.25 | 9,887,509.06 |
| 长期应付职工薪酬 | 39,161,175.37 | 25,155,299.57 | 49,496,881.8 | 37,098,179.18 |
| 预计负债 | 36,025,175.59 | 40,524,285.73 | 37,232,145.01 | 35,879,341.68 |
| 递延收益 | 550,991,222.67 | 589,681,213.34 | 626,654,120.4 | 633,155,235.33 |
| 递延所得税负债 | 816,452,826.21 | 876,708,996.35 | 984,212,561.16 | 998,506,366.24 |
| 其他非流动负债 | 249,262,699.13 | 201,729,073.53 | 200,085,290.41 | 207,897,226.75 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 11,428,680,148 | 11,051,710,878.25 | 10,003,135,409.79 | 10,057,880,361.25 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 137,467,066,427.1 | 140,583,833,874.07 | 139,107,250,634 | 135,331,309,426.82 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 3,707,971,839 | 3,704,610,858 | 3,703,523,491 | 3,703,301,054 |
| 资本公积 | 29,647,771,271.51 | 29,323,700,766.2 | 29,263,188,631.48 | 29,188,056,964.82 |
| 其他综合收益 | -534,279,925.88 | -530,938,297.21 | -528,501,959.89 | -501,002,596.82 |
| 盈余公积 | 2,306,949,383.63 | 2,306,949,383.63 | 2,306,949,383.63 | 2,306,949,383.63 |
| 未分配利润 | 36,547,207,403.71 | 36,061,456,262.21 | 35,245,524,607.07 | 35,364,610,442.49 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 71,675,619,971.97 | 70,865,778,972.83 | 69,990,684,153.29 | 70,061,915,248.12 |
| 少数股东权益 | 12,066,743,749.1 | 12,291,732,944.8 | 12,237,937,041.77 | 12,023,732,069.48 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 83,742,363,721.07 | 83,157,511,917.63 | 82,228,621,195.06 | 82,085,647,317.6 |
| 负债和股东权益合计 | 221,209,430,148.17 | 223,741,345,791.7 | 221,335,871,829.06 | 217,416,956,744.42 |
| 公告日期 | 2025-03-28 | 2024-10-30 | 2024-08-27 | 2024-04-27 |
| 审计意见(境内) | 标准无保留意见 | | | |